Literature DB >> 9131324

Cefdinir versus amoxicillin/clavulanic acid in the treatment of suppurative acute otitis media in children.

M Adler1, P J McDonald, U Trostmann, C Keyserling, K Tack.   

Abstract

An investigator-blinded, randomized, multicenter study was conducted to compare the efficacy and safety of cefdinir and amoxicillin/clavulanate (amoxicillin/CA) in the treatment of pediatric patients with acute suppurative otitis media. Patients 6 months to 12 years of age were randomized in a 1:1:1 ratio to receive cefdinir 14 mg/kg once-daily, cefdinir 7 mg/kg b.i.d., or amoxicillin/CA 13.3 mg/kg t.i.d. Test-of-cure was determined 11 to 16 days post therapy. Of the 752 patients who entered the study, 665 (88%) completed treatment and 595 (79%) were evaluable. Response rates in the three treatment groups were similar. Overall rates of adverse events were statistically lower in the cefdinir once-daily group than in the amoxicillin/CA group. Diarrhea was the most common adverse event in all treatment groups. Cefdinir given either once-daily or twice-daily is a safe and effective treatment for pediatric patients with acute suppurative otitis media.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9131324     DOI: 10.1007/bf01709584

Source DB:  PubMed          Journal:  Eur J Clin Microbiol Infect Dis        ISSN: 0934-9723            Impact factor:   3.267


  8 in total

1.  Importance of patient compliance in effective antimicrobial therapy.

Authors:  D A Hussar
Journal:  Pediatr Infect Dis J       Date:  1987-10       Impact factor: 2.129

Review 2.  Management of acute otitis media and glue ear.

Authors: 
Journal:  Drug Ther Bull       Date:  1995-02

3.  [Clinical studies of cefdinir in pediatric infections].

Authors:  T Shinozaki
Journal:  Jpn J Antibiot       Date:  1991-10

4.  In vitro activity evaluations of cefdinir (FK482, CI-983, and PD134393). A novel orally administered cephalosporin.

Authors:  B M Briggs; R N Jones; M E Erwin; M S Barrett; D M Johnson
Journal:  Diagn Microbiol Infect Dis       Date:  1991 Sep-Oct       Impact factor: 2.803

Review 5.  Otitis media.

Authors:  J O Klein
Journal:  Clin Infect Dis       Date:  1994-11       Impact factor: 9.079

6.  The in-vitro activity of cefdinir (FK482), a new oral cephalosporin.

Authors:  R Wise; J M Andrews; D Thornber
Journal:  J Antimicrob Chemother       Date:  1991-08       Impact factor: 5.790

7.  In vitro evaluation of cefdinir (FK482), a new oral cephalosporin with enhanced antistaphylococcal activity and beta-lactamase stability.

Authors:  M A Cohen; E T Joannides; G E Roland; M A Meservey; M D Huband; M A Shapiro; J C Sesnie; C L Heifetz
Journal:  Diagn Microbiol Infect Dis       Date:  1994-01       Impact factor: 2.803

8.  In vitro activity of cefdinir (FK482) and ten other antibiotics against gram-positive and gram-negative bacteria isolated from adult and pediatric patients.

Authors:  T Sultan; A L Baltch; R P Smith; W Ritz
Journal:  Chemotherapy       Date:  1994 Mar-Apr       Impact factor: 2.544

  8 in total
  3 in total

Review 1.  Optimizing therapy with antibacterial agents: use of pharmacokinetic-pharmacodynamic principles in pediatrics.

Authors:  Christopher M Rubino; John S Bradley
Journal:  Paediatr Drugs       Date:  2007       Impact factor: 3.022

Review 2.  Systemic antibiotics for chronic suppurative otitis media.

Authors:  Lee-Yee Chong; Karen Head; Katie E Webster; Jessica Dew; Peter Richmond; Tom Snelling; Mahmood F Bhutta; Anne Gm Schilder; Martin J Burton; Christopher G Brennan-Jones
Journal:  Cochrane Database Syst Rev       Date:  2021-02-04

3.  Topical versus systemic antibiotics for chronic suppurative otitis media.

Authors:  Lee-Yee Chong; Karen Head; Katie E Webster; Jessica Daw; Peter Richmond; Tom Snelling; Mahmood F Bhutta; Anne Gm Schilder; Martin J Burton; Christopher G Brennan-Jones
Journal:  Cochrane Database Syst Rev       Date:  2021-02-09
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.